Reference |
---|
Li G, Hu J, Cho C, Cui J, Li A, Ren P, et al. Everolimus combined with PD-1 blockade inhibits progression of triple-negative breast cancer. Cell Signal. 2023;109:110729 pubmed publisher
|
Liu N, Zhang J, Yan M, Chen L, Wu J, Tao Q, et al. Supplementation with α-ketoglutarate improved the efficacy of anti-PD1 melanoma treatment through epigenetic modulation of PD-L1. Cell Death Dis. 2023;14:170 pubmed publisher
|
Pan Y, Shu G, Fu L, Huang K, Zhou X, Gui C, et al. EHBP1L1 Drives Immune Evasion in Renal Cell Carcinoma through Binding and Stabilizing JAK1. Adv Sci (Weinh). 2023;10:e2206792 pubmed publisher
|
McEvoy C, Murphy J, Zhang L, Clotet Freixas S, Mathews J, An J, et al. Single-cell profiling of healthy human kidney reveals features of sex-based transcriptional programs and tissue-specific immunity. Nat Commun. 2022;13:7634 pubmed publisher
|
Yang P, Qin H, Li Y, Xiao A, Zheng E, Zeng H, et al. CD36-mediated metabolic crosstalk between tumor cells and macrophages affects liver metastasis. Nat Commun. 2022;13:5782 pubmed publisher
|
Shen H, Huang F, Zhang X, Ojo O, Li Y, Trummell H, et al. Selective suppression of melanoma lacking IFN-γ pathway by JAK inhibition depends on T cells and host TNF signaling. Nat Commun. 2022;13:5013 pubmed publisher
|
Li K, Gong Y, Qiu D, Tang H, Zhang J, Yuan Z, et al. Hyperbaric oxygen facilitates teniposide-induced cGAS-STING activation to enhance the antitumor efficacy of PD-1 antibody in HCC. J Immunother Cancer. 2022;10: pubmed publisher
|
Li F, Zhang H, Wang W, Yang P, Huang Y, Zhang J, et al. T cell receptor β-chain-targeting chimeric antigen receptor T cells against T cell malignancies. Nat Commun. 2022;13:4334 pubmed publisher
|
Liu H, Wu W, Sun G, Chia T, Cao L, Liu X, et al. Optimal target saturation of ligand-blocking anti-GITR antibody IBI37G5 dictates FcγR-independent GITR agonism and antitumor activity. Cell Rep Med. 2022;3:100660 pubmed publisher
|
Takahashi F, Zhang C, Hohjoh H, Raveney B, Yamamura T, Hayashi N, et al. Immune-mediated neurodegenerative trait provoked by multimodal derepression of long-interspersed nuclear element-1. iScience. 2022;25:104278 pubmed publisher
|
Wu J, Li G, Li D, Zhou J, Dong Z, Jiang P. Detection of CD8+ T cell-mediated immune responses to bacterial infection in mice. STAR Protoc. 2021;2:101022 pubmed publisher
|
Woan K, Kim H, Bjordahl R, Davis Z, Gaidarova S, Goulding J, et al. Harnessing features of adaptive NK cells to generate iPSC-derived NK cells for enhanced immunotherapy. Cell Stem Cell. 2021;28:2062-2075.e5 pubmed publisher
|
Klarquist J, Cross E, Thompson S, Willett B, Aldridge D, Caffrey Carr A, et al. B cells promote CD8 T cell primary and memory responses to subunit vaccines. Cell Rep. 2021;36:109591 pubmed publisher
|
Jiang H, Ni H, Zhang P, Guo X, Wu M, Shen H, et al. PD-L1/LAG-3 bispecific antibody enhances tumor-specific immunity. Oncoimmunology. 2021;10:1943180 pubmed publisher
|
Dong L, Chen C, Zhang Y, Guo P, Wang Z, Li J, et al. The loss of RNA N6-adenosine methyltransferase Mettl14 in tumor-associated macrophages promotes CD8+ T cell dysfunction and tumor growth. Cancer Cell. 2021;39:945-957.e10 pubmed publisher
|
Liu Y, Liang G, Xu H, Dong W, Dong Z, Qiu Z, et al. Tumors exploit FTO-mediated regulation of glycolytic metabolism to evade immune surveillance. Cell Metab. 2021;33:1221-1233.e11 pubmed publisher
|
Li H, Kuang X, Liang L, Ye Y, Zhang Y, Li J, et al. The Beneficial Role of Sunitinib in Tumor Immune Surveillance by Regulating Tumor PD-L1. Adv Sci (Weinh). 2021;8:2001596 pubmed publisher
|
Sun Y, Wu L, Zhong Y, Zhou K, Hou Y, Wang Z, et al. Single-cell landscape of the ecosystem in early-relapse hepatocellular carcinoma. Cell. 2021;184:404-421.e16 pubmed publisher
|
Su Y, Chen D, Yuan D, Lausted C, Choi J, Dai C, et al. Multi-Omics Resolves a Sharp Disease-State Shift between Mild and Moderate COVID-19. Cell. 2020;183:1479-1495.e20 pubmed publisher
|
Ye Y, Kuang X, Xie Z, Liang L, Zhang Z, Zhang Y, et al. Small-molecule MMP2/MMP9 inhibitor SB-3CT modulates tumor immune surveillance by regulating PD-L1. Genome Med. 2020;12:83 pubmed publisher
|
Li M, Xiong Y, Li M, Zhang W, Liu J, Zhang Y, et al. Depletion but Activation of CD56dimCD16+ NK Cells in Acute Infection with Severe Fever with Thrombocytopenia Syndrome Virus. Virol Sin. 2020;35:588-598 pubmed publisher
|
Liu H, Kuang X, Zhang Y, Ye Y, Li J, Liang L, et al. ADORA1 Inhibition Promotes Tumor Immune Evasion by Regulating the ATF3-PD-L1 Axis. Cancer Cell. 2020;37:324-339.e8 pubmed publisher
|
Tang X, Zhang S, Peng Q, Ling L, Shi H, Liu Y, et al. Sustained IFN-I stimulation impairs MAIT cell responses to bacteria by inducing IL-10 during chronic HIV-1 infection. Sci Adv. 2020;6:eaaz0374 pubmed publisher
|
Zhao B, Liu P, Fukumoto T, Nacarelli T, Fatkhutdinov N, Wu S, et al. Topoisomerase 1 cleavage complex enables pattern recognition and inflammation during senescence. Nat Commun. 2020;11:908 pubmed publisher
|
Garcia Fabiani M, Comba A, Kadiyala P, Haase S, Núñez F, Altshuler D, et al. Isolation and characterization of immune cells from the tumor microenvironment of genetically engineered pediatric high-grade glioma models using the sleeping beauty transposon system. Methods Enzymol. 2020;632:369-388 pubmed publisher
|
Lu H, Jin L, Huang H, Ha S, Yang H, Chang R, et al. Trophoblast-derived CXCL12 promotes CD56bright CD82- CD29+ NK cell enrichment in the decidua. Am J Reprod Immunol. 2020;83: pubmed publisher
|
Lamichhane R, Galvin H, Hannaway R, de la Harpe S, Munro F, Tyndall J, et al. Type I interferons are important co-stimulatory signals during T cell receptor mediated human MAIT cell activation. Eur J Immunol. 2020;50:178-191 pubmed publisher
|
Lamichhane R, Schneider M, de la Harpe S, Harrop T, Hannaway R, Dearden P, et al. TCR- or Cytokine-Activated CD8+ Mucosal-Associated Invariant T Cells Are Rapid Polyfunctional Effectors That Can Coordinate Immune Responses. Cell Rep. 2019;28:3061-3076.e5 pubmed publisher
|
Saraiva D, Jacinto A, Borralho P, Braga S, Cabral M. HLA-DR in Cytotoxic T Lymphocytes Predicts Breast Cancer Patients' Response to Neoadjuvant Chemotherapy. Front Immunol. 2018;9:2605 pubmed publisher
|